The Phase II trial will use OmniSeq's RNA-seq assay to determine whether patients should be treated with one of two agents combined with BMS' nivolumab.
The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.